Published in Br J Clin Pharmacol on September 01, 1981
Comparison of the effects of clonidine and yohimbine on pupillary diameter at different illumination levels. Br J Clin Pharmacol (2000) 0.96
Does modafinil activate the locus coeruleus in man? Comparison of modafinil and clonidine on arousal and autonomic functions in human volunteers. Psychopharmacology (Berl) (2005) 0.95
A comparative study evaluating the prophylactic efficacy of oral clonidine and tramadol for perioperative shivering in geriatric patients undergoing transurethral resection of prostate. J Anaesthesiol Clin Pharmacol (2014) 0.91
Sedative and cardiovascular effects of medetomidine, a novel selective alpha 2-adrenoceptor agonist, in healthy volunteers. Br J Clin Pharmacol (1987) 0.90
Pharmacological effects and pharmacokinetics of atipamezole, a novel alpha 2-adrenoceptor antagonist--a randomized, double-blind cross-over study in healthy male volunteers. Br J Clin Pharmacol (1990) 0.87
Oral clonidine pretreatment prior to venous cannulation. Anesth Prog (2006) 0.84
Why patients with Alzheimer's disease may show increased sensitivity to tropicamide eye drops: role of locus coeruleus. Psychopharmacology (Berl) (2005) 0.83
A comparison of the haemodynamic and behavioural effects of moxonidine and clonidine in normotensive subjects. Br J Clin Pharmacol (1992) 0.80
The use of clonidine in the management of autonomic overactivity in neuroleptic malignant syndrome. Clin Auton Res (2000) 0.80
Regulation of noradrenaline release by presynaptic receptor systems. Rev Physiol Biochem Pharmacol (1977) 7.62
Sixth gaddum memorial lecture, National Institute for Medical Research, Mill Hill, January 1977. Presynaptic receptors and their role in the regulation of transmitter release. Br J Pharmacol (1977) 6.01
Clinical pharmacology and pharmacokinetics of clonidine. Clin Pharmacol Ther (1976) 3.13
Effects of clonidine withdrawal: possible mechanisms and suggestions for management. Br Med J (1973) 2.87
Centrally mediated decrease in sympathetic tone induced by 2(2,6-dichlorophenylamino)-2 imidazoline (S.T. 155, Catapresan). Eur J Pharmacol (1967) 2.73
Clonidine withdrawal. Mechanism and frequency of rebound hypertension. Br J Clin Pharmacol (1979) 2.72
A functional basis for classification of alpha-adrenergic receptors. Life Sci (1977) 2.69
Evidence for two distinct types of postsynaptic alpha-adrenoceptor in vascular smooth muscle in vivo. Br J Pharmacol (1979) 2.39
Novel alpha2-adrenoreceptors primarily responsible for inducing human platelet aggregation. Nature (1979) 2.17
Clonidine withdrawal in hypertension. Changes in blood-pressure and plasma and urinary noradrenaline. Lancet (1977) 2.01
Pharmacokinetics and concentration-effect relationships of intervenous and oral clonidine. Clin Pharmacol Ther (1977) 1.91
Action of -adrenergic blocking drugs on the sympathetic centres and their interactions with the central sympatho-inhibitory effect of clonidine. Arzneimittelforschung (1973) 1.71
Effects of clonidine and BS 100-141 on the EEG sleep pattern in rats. Eur J Pharmacol (1975) 1.36
Investigations into the mechanism of the hypotensive effect of 2-(2,6-dichlorphenylamino)-2-imidazoline-HCl. Eur J Pharmacol (1967) 1.30
Clonidine overdose. Br Med J (1975) 1.21
Effects of clonidine on biochemical indices of sympathetic function and plasma renin activity in normotensive man. Clin Sci Mol Med (1977) 1.17
Pharmacokinetic and concentration-effect relationships of clonidine in essential hypertension. Eur J Clin Pharmacol (1977) 1.16
Interaction of DOPA decarboxylase inhibitors with the effect of alpha-methyldopa on blood pressure and tissue monoamines in rats. Acta Pharmacol Toxicol (Copenh) (1969) 1.05
Pre- and postsynaptic effects of alpha-agonists in the anococcygeus muscle of the pithed rat. Eur J Pharmacol (1979) 0.96
The effect of clonidine and penbutolol, respectively on catecholamines in blood and urine, plasma renin activity and urinary aldosterone in hypertensive patients. Arch Int Pharmacodyn Ther (1975) 0.96
Guanfacine: effects of long-term treatment and withdrawal. Br J Clin Pharmacol (1980) 0.96
Circulatory effects at rest and exercise of clonidine, an imidazoline derivative with hypotensive properties. Lancet (1969) 0.96
Pharmacokinetics of clonidine and its relation to the hypotensive effect in patients. Br J Clin Pharmacol (1978) 0.96
Apparent resistance to hypotensive effect of clonidine. Br Med J (1977) 0.96
The central hypotensive effect of clonidine. Studies in tetraplegic subjects. Clin Pharmacol Ther (1977) 0.92
Observations on the hypotensive action of "Catapres" (ST 155) in man. Med J Aust (1968) 0.91
A newly developed precise and sensitive radioimmunoassay for clonidine. Arzneimittelforschung (1979) 0.90
[Critical considerations on the method of action of 2-(2,6-dichlorophenylamino)-2-imidazoline-hydrochloride]. Arzneimittelforschung (1966) 0.86
Clonidine and sympathetic activity during sleep. Clin Sci (Lond) (1979) 0.86
Clinical experience with guanfacine in long-term treatment of hypertension. Part II: adverse reactions to guanfacine. Br J Clin Pharmacol (1980) 0.86
The central hypotensive action of clonidine and propranolol in animals and man. Prog Brain Res (1977) 0.83
Intravenous clonidine in hypertensive patients. Clin Pharmacol Ther (1973) 0.82
Changes in blood pressure, heart rate, and sympathetic activity on abrupt withdrawal of tiamenidine (HOE 440) in essential hypertension. Eur J Clin Pharmacol (1980) 0.80
Withdrawal of guanfacine after long-term treatment in essential hypertension. Observations on blood pressure and plasma and urinary noradrenaline. Eur J Clin Pharmacol (1981) 0.77
Relationship between clonidine kinetics and its blood pressure effects. Acta Med Scand Suppl (1979) 0.77
Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature (1998) 8.75
White-coat hypertension as a cause of cardiovascular dysfunction. Lancet (1996) 4.68
Epidemiology of respiratory syncytial virus infection in Washington, D.C. I. Importance of the virus in different respiratory tract disease syndromes and temporal distribution of infection. Am J Epidemiol (1973) 3.77
Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet (1998) 3.41
Clinical pharmacology and pharmacokinetics of clonidine. Clin Pharmacol Ther (1976) 3.13
Analysis of the pressor dose response. Clin Pharmacol Ther (1982) 2.44
Immediate cardiovascular responses to oral prazosin--effects of concurrent beta-blockers. Clin Pharmacol Ther (1981) 2.36
The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth. EMBO J (1999) 2.23
A pharmacodynamic and pharmacokinetic assessment of a new alpha-adrenoceptor antagonist, doxazosin (UK33274) in normotensive subjects. Br J Clin Pharmacol (1982) 2.06
Placebo-controlled trial of atenolol in treatment of pregnancy-associated hypertension. Lancet (1983) 2.03
Clonidine withdrawal in hypertension. Changes in blood-pressure and plasma and urinary noradrenaline. Lancet (1977) 2.01
Topographic detection of photorefractive keratectomy. Ophthalmology (1998) 1.97
Coordinating and standardizing long-term care: evaluation of the west of Scotland shared-care scheme for hypertension. Br J Gen Pract (1994) 1.92
Pharmacokinetics and concentration-effect relationships of intervenous and oral clonidine. Clin Pharmacol Ther (1977) 1.91
Doxazosin, an alpha 1-adrenoceptor antagonist: pharmacokinetics and concentration-effect relationships in man. Br J Clin Pharmacol (1983) 1.89
Pharmacodynamics of converting enzyme inhibition: the cardiovascular, endocrine and autonomic effects of MK421 (enalapril) and MK521. Br J Clin Pharmacol (1982) 1.81
Effect of intravenous adrenaline on electrocardiogram, blood pressure, and serum potassium. Br Heart J (1983) 1.79
"Third drug" trial: comparative study of antihypertensive agents added to treatment when blood pressure remains uncontrolled by a beta blocker plus thiazide diuretic. Br Med J (Clin Res Ed) (1984) 1.69
Cardiovascular reflexes in Parkinsonism. Clin Sci (1971) 1.62
Idiopathic Parkinsonism treated with an extracerebral decarboxylase inhibitor in combination with levodopa. Br Med J (1971) 1.60
Brain concentration of propranolol in relation to hypotensive effect in the rabbit with observations on brain propranolol levels in man. J Pharmacol Exp Ther (1975) 1.56
The effects of cardioselective and non-selective beta-adrenoceptor blockade on the hypokalaemic and cardiovascular responses to adrenomedullary hormones in man. Clin Sci (Lond) (1983) 1.56
Evidence of parasympathetic activity of the angiotensin converting enzyme inhibitor, captopril, in normotensive man. Clin Sci (Lond) (1985) 1.49
Verapamil pharmacokinetics and apparent hepatic and renal blood flow. Br J Clin Pharmacol (1985) 1.46
Central hypotensive effect of propranolol in the rabbit. Br J Pharmacol (1973) 1.44
Superoxide anion production is increased in a model of genetic hypertension: role of the endothelium. Hypertension (1999) 1.44
The importance of central adrenergic neurones in renal hypertension in rabbits. J Physiol (1974) 1.43
Effects of single and repeated doses of omeprazole on gastric acid and pepsin secretion in man. Gut (1984) 1.36
Technical report: quantitative assessment of diaphragmatic movement--a reproducible method using ultrasound. Clin Radiol (1992) 1.30
Desmethylimipramine and the hypotensive action of clonidine in the rabbit. Br J Pharmacol (1972) 1.30
Acute and chronic effects of the converting enzyme inhibitors enalapril and lisinopril on reflex control of heart rate in normotensive man. J Hypertens (1985) 1.29
The effect of captopril on the reflex control heart rate: possible mechanisms. Br J Clin Pharmacol (1985) 1.29
Infections in 18,000 infants and children in a controlled study of respiratory tract disease. II. Variation in adenovirus infections by year and season. Am J Epidemiol (1972) 1.27
Central noradrenergic neurones and the cardiovascular actions of clonidine in the rabbit. Br J Pharmacol (1973) 1.27
Prazosin disposition in young and elderly subjects. Br J Clin Pharmacol (1981) 1.24
A pragmatic approach to the pressor dose-response as an index of vascular reactivity and adrenoceptor function in man. Br J Clin Pharmacol (1987) 1.22
Evidence for postjunctional vascular alpha 2-adrenoceptors in peripheral vascular regulation in man. Clin Sci (Lond) (1983) 1.22
The effect of nisoldipine on apparent liver blood flow and effective renal plasma flow. Br J Clin Pharmacol (1985) 1.20
Idiopathic parkinsonism treated with bromocriptine. Lancet (1975) 1.20
Effects of the angiotensin converting enzyme inhibitor, captopril, in essential hypertension. Br J Clin Pharmacol (1982) 1.19
Endothelin-1-induced reductions in cerebral blood flow: dose dependency, time course, and neuropathological consequences. J Cereb Blood Flow Metab (1993) 1.18
Sensitivity to cerebral ischaemic insult in a rat model of stroke is determined by a single genetic locus. Nat Genet (1997) 1.18
Effects of clonidine on biochemical indices of sympathetic function and plasma renin activity in normotensive man. Clin Sci Mol Med (1977) 1.17
Oral pharmacokinetics of omeprazole. Eur J Clin Pharmacol (1984) 1.16
Pharmacokinetic and concentration-effect relationships of clonidine in essential hypertension. Eur J Clin Pharmacol (1977) 1.16
Preliminary experience with a hospital blood pressure follow up clinic with nurse practitioner assessment and microprocessor based data retrieval. Br Med J (Clin Res Ed) (1984) 1.16
The pharmacokinetics, antihistamine and concentration-effect relationship of ebastine in healthy subjects. Br J Clin Pharmacol (1988) 1.16
Kinetic-dynamic relations and individual responses to enalapril. Hypertension (1990) 1.16
Policies for managing hypertensive patients: a survey of the opinions of British specialists. J Hum Hypertens (1990) 1.14
Prior thiazide diuretic treatment increases adrenaline-induced hypokalaemia. Lancet (1983) 1.14
Age and the pharmacokinetics of angiotensin converting enzyme inhibitors enalapril and enalaprilat. Br J Clin Pharmacol (1986) 1.13
The role of adrenal medullary catecholamines in potassium homoeostasis. Clin Sci (Lond) (1984) 1.13
[3H]yohimbine and [3H]idazoxan bind to different sites on rabbit forebrain and kidney membranes. Eur J Pharmacol (1988) 1.13
Atenolol disposition in young and elderly subjects. Br J Clin Pharmacol (1982) 1.13
Platelet alpha-adrenoceptors--a valid model for brain or vascular adrenoceptors? Br J Clin Pharmacol (1986) 1.12
Interaction between clonidine and desipramine in man. Br Med J (1973) 1.11
Effect of age on the responsiveness of vascular alpha-adrenoceptors in man. J Cardiovasc Pharmacol (1982) 1.10
Plasma noradrenaline concentration in essential hypertension during long-term beta-adrenoceptor blockade with oxprenolol. Br J Clin Pharmacol (1980) 1.09
Nifedipine does not influence adrenaline induced hypokalaemia in man. Br J Clin Pharmacol (1983) 1.09
Acute thermoregulatory and cardiovascular effects of 6-hydroxydopamine administered centrally in rabbits and cats. Br J Pharmacol (1972) 1.09
Central and peripheral adrenergic mechanisms in the development of deoxycorticosterone-saline hypertension in rats. Circ Res (1975) 1.07
The experiences of an acute stroke unit--implications for multicentre acute stroke trials. J Neurol Neurosurg Psychiatry (1993) 1.06
The influence of naloxone on the circulatory effects of captopril. Br J Clin Pharmacol (1984) 1.06
Effects of angiotensin converting enzyme inhibitor, perindopril, on autonomic reflexes. Eur J Clin Pharmacol (1986) 1.05
Blood pressure in genetically hypertensive rats. Influence of the Y chromosome. Hypertension (1995) 1.05
Cardiovascular effects of intracerebroventricular d-, l- and dl-propranolol in the conscious rabbit. J Pharmacol Exp Ther (1974) 1.05
Plasma concentration of levodopa in Parkinsonism before and after inhibition of peripheral decarboxylase. J Neurol Sci (1972) 1.05
Nifedipine: individual responses and concentration-effect relationships. Hypertension (1988) 1.03
Concentration effect modelling with converting enzyme inhibitors in man. Br J Clin Pharmacol (1983) 1.03
Hypercholesterolaemia in treated hypertensives: a controlled trial of intensive dietary advice. J Hypertens Suppl (1989) 1.03
The pharmacodynamics and dose-response relationships of the angiotensin converting enzyme inhibitor, cilazapril, in essential hypertension. Br J Clin Pharmacol (1986) 1.03
Sedative and cardiovascular effects of clonidine and nitrazepam. Clin Pharmacol Ther (1980) 1.02
A comparison of the management of hypertensive patients by nurse practitioners compared with conventional hospital care. J Hum Hypertens (1990) 1.02
Effect of naloxone on the actions of captopril. Clin Pharmacol Ther (1985) 1.02
Regional impairment of cerebral oxidative metabolism in Parkinson's disease. J Neurol Neurosurg Psychiatry (1979) 1.02
Haemodynamic and humoral effects of oral perindopril, an angiotensin converting enzyme inhibitor, in man. Br J Clin Pharmacol (1987) 1.02
Calcium antagonists decrease adrenal and vascular responsiveness to angiotensin II in normal man. Clin Sci (Lond) (1981) 1.01
Decreased vascular responsiveness to noradrenaline following regular ethanol consumption. Br J Clin Pharmacol (1985) 1.00
Vascular and aldosterone responses to angiotensin II in normal humans: effects of nicardipine. J Cardiovasc Pharmacol (1986) 1.00
Enalapril and autonomic reflexes and exercise performance. J Hypertens Suppl (1983) 1.00
Differences in first dose response to angiotensin converting enzyme inhibition in congestive heart failure: a placebo controlled study. Br Heart J (1991) 1.00
Measuring therapy adherence in Parkinson's disease: a comparison of methods. J Neurol Neurosurg Psychiatry (2006) 1.00
Letter: Clonidine overdose. Br Med J (1975) 0.99
Simultaneous assay of 3,4-dihydroxyphenylethylene glycol and norepinephrine in human plasma by high-performance liquid chromatography with electrochemical detection. J Chromatogr (1985) 0.99
The symptoms of patients treated for Parkinson's disease. Clin Neuropharmacol (1985) 0.99
Plasma concentration of alpha-methyldopa and sulphate conjugate after oral administration of methyldopa and intravenous administration of methyldopa and methyldopa hydrochloride ethyl ester. Eur J Clin Pharmacol (1975) 0.99
Effect of nifedipine on blood pressure and adrenocortical responses to trophic stimuli in humans. J Cardiovasc Pharmacol (1982) 0.98
Parkinsonism treated with 3-O-methyldopa. Clin Pharmacol Ther (1973) 0.98
Calcium antagonists and hormone release: effect of nifedipine on luteinizing hormone-releasing hormone and thyrotropin-releasing hormone-induced pituitary hormone release. J Clin Endocrinol Metab (1983) 0.98
The effect of age on the responses of human isolated arteries to noradrenaline. Br J Clin Pharmacol (1982) 0.97
Statin administration prior to ischaemic stroke onset and survival: exploratory evidence from matched treatment-control study. Eur J Neurol (2005) 0.97
The effect of enalapril on baroreceptor mediated reflex function in normotensive subjects. Br J Clin Pharmacol (1986) 0.97
The haemodynamic and humoral effects of treatment for one month with the angiotensin converting enzyme inhibitor perindopril in salt replete hypertensive patients. Eur J Clin Pharmacol (1987) 0.97
Effects of intravenous S-9780, an angiotensin-converting enzyme inhibitor, in normotensive subjects. J Cardiovasc Pharmacol (1987) 0.97
Does labetalol increase excretion of urinary catecholamines? Br Med J (1978) 0.97
Antihypertensive drugs in the elderly--the evidence of benefit. Cardiovasc Drugs Ther (2001) 0.97
The determination of labetalol in plasma by high-performance liquid chromatography using fluorescence detection. J Pharmacol Methods (1981) 0.97
Significance of plasma dopamine beta-hydroxylase activity as an index of sympathetic neuronal function. Proc Natl Acad Sci U S A (1974) 0.96
Comparison of enalapril and atenolol in mild to moderate hypertension. Am J Med (1989) 0.96
Guanfacine: effects of long-term treatment and withdrawal. Br J Clin Pharmacol (1980) 0.96